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We expressed concern1 early in the COVID-19 pandemic that people with intellectual and developmental disabilities 
would disproportionately experience the health burdens of COVID-19 due to:  
1) higher prevalence of underlying medical conditions that can increase the severity of COVID-19 outcomes;2,3  
2) a disproportionate percentage of people with intellectual and developmental disabilities living in group home 
residences;4  
3) communications about COVID-19 prevention and treatment advice that is not accessible to people with 
disability;5,6  
4) historic and ongoing status as a vulnerable, and often marginalized, health disparities population.7,8  
 
Unfortunately, these concerns were on target. Our first study included a large sample of people with and without 
intellectual and developmental disabilities who had been diagnosed with COVID-19 and confirmed a higher 
prevalence of underlying conditions among those with intellectual and developmental disabilities at all ages. It also 
indicated a higher case-fatality rate for people with intellectual and developmental disabilities at ages up to age 74.9 Our 
second study on group residential settings revealed that in New York State, people with intellectual and developmental 
disabilities living in group homes had a case rate 4 times higher, and case-fatality rate 1.9 times higher than the overall 
state population.10 A more recent study demonstrated that the higher case rate for those living in congregate settings 
(group homes and health care facilities) is likely associated with the number of residents per facility. However, the 
higher case-fatality rate is likely due to the higher prevalence of pre-existing conditions.11 Finally, a study in progress 
documents that these trends are consistent for people with intellectual and developmental disabilities across the U.S.12 
 
Vaccination priorities reveal our values 
Just distribution of vaccines requires prioritization decisions that consider medical need, social marginalization, and 
overall health-related harm and benefits.13 The evidence is clear that people with intellectual and developmental 
disabilities experience disproportionately severe COVID-19 outcomes and should be prioritized in the allocation of 
COVID-19 vaccines. Vaccine allocation decisions will speak volumes about whether we do—or do not—value the lives 
of people with intellectual and developmental disabilities. We concur with the recommendation from the National 
Academies of Sciences, Engineering and Medicine that people with intellectual and developmental disabilities residing in 
congregate settings, as well as their care staff, should receive priority in vaccination distribution.14 However, we are 




and developmental disabilities population, may be short-sighted. This vulnerable group experiences greater prevalence 
of pre-existing conditions that can exacerbate the severity of COVID-19. They also often need direct, not socially-
distanced, support. Thus, it is imperative to prioritize all people with intellectual and developmental disabilities for timely 
access to the COVID-19 vaccine. Caring for those with the greatest need is a moral responsibility. Whether, and how, we 
prioritize people with intellectual and developmental disabilities in COVID-19 vaccine allocation will reveal the extent 
to which we value this group within our society. 
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